Bavarian Nordic gains US vaccine contract worth USD 1.6 bn  

2007.06.06
Danish biotech company Bavarian Nordic has gained an exclusive contract from the US Department of Health and Human Services for the delivery of 20 million doses of smallpox vaccine
Danish biotech company Bavarian Nordic has gained an exclusive contract from the US Department of Health and Human Services (HHS) for the delivery of 20 million doses of the company's Imvamune smallpox vaccine for the strategic national stockpile. Bavarian Nordic received notification of the procurement in April as reported on this website. The total value of the deal including contractional options is USD 1.6 bn.
 
Rolf Sass Sørensen, head of investor relations of Bavarian Nordic, says: "This is a commercial breakthrough and the order radically changes the company." "We have shown once and for all that our technology and vaccine is the standard, and that will open the world market."
 
Sørensen says Bavarian Nordic plans to further develop its pipeline to avoid being in a situation where the company is dependent on a single product: "We will use the next years to buy new technologies and projects which make us less vulnerable and also expand our commercial opportunities. We are very conscious of running a business for our shareholders, and we are aiming to find ways to support business and growth."
 
Bavarian Nordic has operations in Denmark, Germany, the US and Singapore. The company's patented MVA-BN technology is one of the world's safest multivalent vaccine vectors for development of vaccines against infectious diseases (smallpox and HIV) and cancer. Bavarian Nordic has ongoing development contracts with the US government to develop Imvamune as a safe third-generation smallpox vaccine. The news was reported by financial daily newspaper Børsen and on Bavarian Nordic's website.
 
Link > Bavarian Nordic  

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×